We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MAVI:BISTMavi Giyim Sanayi ve Ticaret A.S. Analysis

Data as of 2026-03-17 - not real-time

TRY 41.18

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Mavi Giyim trades at TRY 41.18, roughly 37% above its DCF‑derived fair value of TRY 30.12, yet the forward P/E of 2.48 suggests the market is pricing in substantial earnings upside. The company posted a modest revenue decline of 1.3% but improved operating margins to 15.7% and maintains a healthy gross margin of 50.3%, underpinning cash generation (operating cash flow ~TRY 7.0 bn). Dividend yield sits at 2.83% with a payout ratio near 55%, indicating sustainable returns for income‑focused investors. Technicals are mixed: RSI at 36 points to oversold conditions, while the MACD remains bearish and volume is tapering, hinting at short‑term caution. Nonetheless, analysts project a 54% upside (median target TRY 64.5) and rate the stock a strong buy, reflecting confidence in margin recovery and brand positioning. With a low beta of 0.12 and a 30‑day volatility of 36%, the stock offers limited market‑wide risk but heightened exposure to Turkey‑specific dynamics. Overall, the fundamentals, dividend sustainability, and analyst optimism tilt the case toward a buying stance across horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price near support at TRY 38.56 with upside potential
  • RSI indicating oversold conditions
  • Attractive dividend yield of 2.83%

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward P/E of 2.48 signaling significant earnings upside
  • Margin expansion and strong cash flow generation
  • Analyst consensus strong‑buy with median price target TRY 64.5

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustainable dividend policy and low payout ratio volatility
  • Low beta (0.12) indicating limited systematic risk
  • Long‑term upside of ~55% relative to current price

Key Metrics & Analysis

Financial Health

Revenue Growth-1.30%
Profit Margin4.73%
P/E Ratio19.2
ROE13.63%
ROA11.22%
Debt/Equity27.32
P/B Ratio2.4
Op. Cash FlowTRY7.0B
Free Cash FlowTRY1.6B

Technical Analysis

TrendNeutral
RSI36.3
SupportTRY 38.56
ResistanceTRY 50.75
MA 20TRY 44.04
MA 50TRY 45.74
MA 200TRY 41.22
MACDBearish
VolumeDecreasing
Fear & Greed Index79.45

Valuation

Fair ValueTRY 30.12
Target PriceTRY 63.70
Upside/Downside54.69%
GradeUndervalued
TypeBlend
Dividend Yield2.83%

Risk Assessment

Beta0.29
Volatility36.09%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskHigh
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.